CareDx (CDNA) Asset Writedowns and Impairment (2021 - 2023)

CareDx (CDNA) posted Asset Writedowns and Impairment of $1.0 million for Q1 2023, up 19.05% sequentially from $840000.0 in Q3 2022.

CareDx (CDNA) Asset Writedowns and Impairment (2021 - 2023) Analysis & Trends

CareDx has reported Asset Writedowns and Impairment for 3 years, with the latest figure at $1.0 million in Q1 2023.

Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $1.0 million in Q1 2023, while the trailing twelve-month figure through Dec 2023 was $1.0 million (up 19.05% YoY) and the FY2025 annual result came in at $2.3 million, changed N/A from the prior year.
Asset Writedowns and Impairment improved to $1.0 million in Q1 2023 per CDNA's latest filing, from $840000.0 in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $2.4 million in Q4 2021 and troughed at $840000.0 in Q3 2022.
A 3-year average of $1.4 million and a median of $1.0 million in 2023 frame the typical range for Asset Writedowns and Impairment.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Thermo Fisher Scientific	234.15 Bn	230.09 Bn	8.34 Bn
2	Danaher	152.10 Bn	147.75 Bn	3.61 Bn
3	Natera	48.48 Bn	47.38 Bn	486.15 Mn
4	Agilent Technologies	44.35 Bn	42.55 Bn	990.00 Mn
5	Iqvia Holdings	43.68 Bn	41.60 Bn	1.44 Bn
6	Idexx Laboratories	43.02 Bn	42.83 Bn	779.09 Mn
7	Illumina	34.39 Bn	33.22 Bn	770.00 Mn
8	Mettler Toledo International	28.29 Bn	28.24 Bn	650.22 Mn
9	Labcorp Holdings	27.51 Bn	27.37 Bn	1.11 Bn
10	CareDx	2.69 Bn	2.31 Bn	116.03 Mn

Download Data